{
  "docId": "019de072-13bd-74ea-b396-bd93a39bdc94",
  "docSlug": "96003a7ba08cc5f25ee9ab531ee7db70",
  "documentTitle": "Alkermes | Results Presentation Deck | 18 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 18,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-13bd-74ea-b396-bd93a39bdc94/15",
  "deckHref": "/decks/019de072-13bd-74ea-b396-bd93a39bdc94",
  "deckJsonHref": "/decks/019de072-13bd-74ea-b396-bd93a39bdc94.json",
  "deckAnchorHref": "/decks/019de072-13bd-74ea-b396-bd93a39bdc94#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Commercial Portfolio: Execute successful LYBALVI launch, drive VIVITROL growth, increase ARISTADA share.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4580ecac-20e5-40eb-a1db-9ed33db1078c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "Nemvaleukin: Advance ARTISTRY-6 & 7, evaluate dosing, pursue collaborations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f2aae97-87e9-4485-ab60-2bb3dd01be1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "list",
      "text": "Financial: Execute against 2022 expectations and long-term profitability targets.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d78a1137-2080-4a0f-95e4-0ce762119936",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "list",
      "text": "Early-stage Pipeline: ALKS 1140 preclinical work, ALKS 2680 IND-enabling, advance engineered cytokines.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efb28fda-0964-4b6a-8315-057abb64508f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Looking Ahead: 2022 Strategic Priorities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b43f01b-bbe8-4b45-b239-5f71189e7f85",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 15,
      "beatId": "e2c49767-f071-4ab7-bc81-a64420b519ad",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The looking ahead slide highlights Alkermes' strategic priorities for 2022",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 15,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "dd486a4f-da04-41ec-93d4-0011baf8637f",
      "evidence": "The looking ahead slide highlights the importance of Alkermes' strategic priorities for 2022",
      "position": 1,
      "objective": "Why are Alkermes' strategic priorities important now?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}